Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial

Published:2022-03 Issue:3 Volume:23 Page:374-381
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fennell Dean A,King Amy,Mohammed Seid,Greystoke Alastair,Anthony Sarah,Poile Charlotte,Nusrat Nada,Scotland Molly,Bhundia Vina,Branson Amy,Brookes Cassandra,Darlison Liz,Dawson Alan G,Gaba Aarti,Hutka Margaret,Morgan Bruno,Bajaj Amrita,Richards Cathy,Wells-Jordan Peter,Thomas Anne,Fennell Dean A.,King Amy,Greystoke Alastair,Anthony Sarah,Moody Sam,Poille Charlotte,Nusrat Nada,Scotland Molly,Bhundia Vina,Branson Amy,Brookes Cassandra,Darlison Liz,Dawson Alan G.,Gaba Aarti,Hutka Margaret,Morgan Bruno,Bajaj Amrita,Richards Cathy,Wells-Jordan Peter,Nicolson Adrian,Underwood Judith,Sodha-Ramdeen Azmina,Cowley Caroline,Barber Shaun,Thomas Anne

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Integrative molecular characterization of malignant pleural mesothelioma;Hmeljak;Cancer Discov,2018

2. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations;Bueno;Nat Genet,2016

3. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial;Fennell;Lancet Oncol,2021

4. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial;Pinto;Lancet Oncol,2021

5. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma;Cheng;Cancer Res,1994

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing precision: A review of targeted approaches in pleural mesothelioma;Critical Reviews in Oncology/Hematology;2024-11

2. Targeted Therapy in Mesotheliomas: Uphill All the Way;Cancers;2024-05-22

3. Loss of p16 Immunoexpression and Deletions of CDKN2A in the Progression of Extramammary Paget Disease: An Immunohistochemical and Genetic Study of 24 Invasive/Metastatic Cases;The American Journal of Dermatopathology;2024-04-23

4. Case report: Navigating treatment pathways for cardiac intimal sarcoma with PDGFRβ N666K mutation;Frontiers in Oncology;2024-04-05

5. Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma;Cancers;2024-03-22